Return to content in this issue

Safe administration of SARS-CoV-2 vaccine after desensitization to a biologic containing polysorbate 80 in a patient with polyethylene glycol-induced severe anaphylaxis and sensitization to polysorbate 80

Nin-Valencia A¹, Fiandor A^1,2,3, Lluch M^1,2,3, Quirce S^1,2,4, Caballero T^1,2,5, Heredia Revuelto R¹, González-Muñoz M^2,6, Caballero ML^1,2, Cabañas R<sup>1,2,3,5

1</sup>Department of Allergy, Hospital Universitario La Paz, Madrid, Spain.
²Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
³PIELenRed Consortium.
⁴Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES)
⁵Centro de Investigación en Red de Enfermedades Raras (CIBERER, U754).
⁶Department of Immunology, Hospital Universitario La Paz, Madrid, Spain.

J Investig Allergol Clin Immunol 2023; Vol. 33(2)
doi: 10.18176/jiaci.0830

• Abstract
• Supplemental Materials

Key words: Polyethylene glycol, Polysorbates, Allergy, Desensitization, Infliximab, SARS-CoV-2 vaccine

	Title	Type	Size
	doi10.18176_jiaci.0830_supplemental-materials.pdf	pdf	133.95 Kb